Genetically Modified Phage Biomarker Detection System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting biomarkers such as anti-Sap2-IgG in immunocompromised patients, especially cancer patients, are inefficient and time-consuming, leading to delayed diagnosis and increased mortality rates due to invasive fungal infections like Candida albicans, as they require several days for results and struggle with low-level marker detection.
Innovation Solution
Genetically modified filamentous phages are engineered to display specific peptides for biomarker recognition and magnetic nanoparticle binding, allowing for rapid magnetic enrichment and detection of biomarkers like anti-Sap2-IgG using ELISA, significantly reducing detection time and improving sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blood culture method is used for diagnosis, then reliability of diagnosis is improved, but detection time is excessively long (5 days)
Solution Approach 1:
The patent introduces a phage-displayed peptide library as an intermediary system to detect anti-Sap2-IgG antibodies. The peptides displayed on phage surfaces act as mediators that specifically bind to the target antibodies, enabling rapid detection without requiring traditional blood culture methods. This intermediary approach allows direct antibody detection in patient serum within hours rather than days.
Solution Approach 2:
The patent replaces the mechanical/time-intensive blood culture process with a molecular recognition system based on phage-peptide-antibody interactions. Instead of waiting for bacterial growth and observation, the system uses specific binding events between displayed peptides and anti-Sap2-IgG antibodies, which can be detected rapidly through various readout methods including ELISA and flow cytometry.
2Difficulty of detecting and measuring
If ELISA is used for protein detection, then detection capability is provided, but sensitivity is insufficient for low-level marker proteins
Solution Approach 1:
The patent creates a composite detection system combining phage particles with displayed peptides. The phage structure provides a stable platform for displaying multiple copies of the peptide ligand, while the peptides provide specific binding to the target antibody. This composite approach enhances sensitivity compared to traditional ELISA by increasing the number of binding sites per particle and enabling signal amplification strategies.
Solution Approach 2:
The patent changes the detection parameters by using phage-displayed peptides with high affinity for anti-Sap2-IgG. The system can detect antibodies at concentrations as low as 1:640 dilution, which represents a significant sensitivity improvement over conventional ELISA methods. The phage system allows for optimization of binding parameters through selection of high-affinity peptide variants.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves rapid detection of anti-Sap2-IgG within hours, with a two-order magnitude lower detection limit than traditional methods, enhancing the early detection of Candida albicans infections and improving patient outcomes by providing timely antifungal therapy.
Implementation Method 1
a first peptide able to bind to a magnetic nanoparticle
Implementation Method 2
a second peptide able to bind with high specificity to a predetermined biomarker protein or peptide
Data Source
AI summary
Disclosed are genetically-modified phages, comprising a first nucleic acid sequence encoding at least a first peptide able to bind to a magnetic nanoparticle, and a second nucleic acid sequence encoding at least a second peptide able to bind with high specificity to a predetermined biomarker, and a method for using the genetically-modified phage displaying the first peptide and second peptide in a method for analyzing a fluid sample for the predetermined biomarker.